Jazz Pharmaceuticals announced that Ziihera (zanidatamab) combined with chemotherapy, with or without tislelizumab, significantly improves overall survival in HER2-positive advanced gastroesophageal adenocarcinoma. The Phase 3 HERIZON-GEA-01 trial showed a median overall survival of 27 months for Ziihera plus tislelizumab and chemotherapy, compared to 19.6 months with trastuzumab plus chemotherapy, reducing death risk by 24-35%. Nearly 40% of patients treated with Ziihera plus tislelizumab and chemotherapy were alive at three years, marking a new standard for first-line treatment. The regimens were recently FDA-approved and included in clinical guidelines, with manageable safety profiles confirmed by longer follow-up.
Ziihera® (zanidatamab-hrii) combinations in advanced gastroesophageal adenocarcinoma provide context for health sector trading as of Oct 23, 2026 21:32 WIB. On Pluang, out of 150 priced Health-sector US stocks, 19 rose and 130 fell today. Notable movers include TNGX at USD 22.95 with a -17.81% change and 100% buy order activity, NUWE at USD 0.44 down 9.86% with 100% buy orders, and INO at USD 0.91 up 8.05% with 73% sell orders. The most notable figure is the 130 stocks that declined.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
